NASDAQ$MYGN
Myriad Genetics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2022.
Myriad Genetics reported revenue of $179.3 million for the quarter ended June 30, 2022, representing a 7% year-over-year increase excluding revenue from divested businesses and a 9% sequential increase from the first quarter of 2022. The company's diluted GAAP EPS was $(0.18) and adjusted EPS was $0.04 in the second quarter of 2022. The company updated its fiscal year 2022 financial guidance to reflect an additional $20 million investment in research and development, technology, and sales and marketing programs. The company ended the quarter with $283.6 million in cash, cash equivalents and investments.
- Revenue of $179.3 million for the quarter ended June 30, 2022, with a 7% year-over-year increase excluding revenue from divested businesses.
- Diluted GAAP earnings per share (EPS) of $(0.18) and adjusted EPS of $0.04 in the second quarter of 2022.
- Fiscal year 2022 financial guidance updated to reflect an additional $20 million investment in research and development, technology, and sales and marketing programs.
- Ended the quarter with $283.6 million in cash, cash equivalents and investments.
Headline financials
Revenue & EPS history
Myriad Genetics · Revenue · Quarterly
$179M
Revenue by segment
Myriad Genetics · $146M total across 3 segments · Q2 2022
- Hereditary Cancer$79.4M-7.7%54.3%
- Tumor Profiling$33.5M+14.7%22.9%
- Prenatal$33.3M+13.3%22.8%
Forward guidance
Myriad Genetics provided its fiscal year 2022 financial guidance, reiterating its revenue and gross margin guidance and updating its guidance for total operating expense and earnings per share. The company is increasing its fiscal year 2022 operating expense guidance by approximately $20.0 million and plans to make opportunistic incremental investments in research and development, technology and sales and marketing programs.
Tailwinds
- Revenue: $670 - $700 million
- Gross Margin: 70% - 72%
Headwinds
- GAAP Operating Expenses: $585 - $595 million
- Adjusted (Non-GAAP) Operating Expenses: $490 - $500 million
- GAAP Earnings (Loss) Per Share: $(1.10) - $(1.00)
- Adjusted (Non-GAAP) Earnings (Loss) Per Share: $(0.10) - $0.00
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-2.7%
Avg return
Earnings day
-6.0%
Avg return
5 days after
-4.5%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+20.4%
Q3 2017
Best reaction
-43.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -18.3% | -16.3% | -9.1% | |
| Q4 2025 | +5.7% | +5.3% | +5.5% | |
| Q3 2025 | -21.0% | -23.0% | -10.4% | |
| Q1 2025 | -41.3% | -41.5% | -30.0% | |
| Q4 2024 | -14.8% | -22.1% | -33.1% | |
| Q3 2024 | -0.9% | -8.0% | -13.9% | |
| Q2 2024 | +3.1% | +8.2% | +7.0% | |
| Q1 2024 | +19.9% | +27.5% | +11.7% | |
| Q4 2023 | -5.8% | -3.3% | -7.0% | |
| Q3 2023 | +4.3% | -3.3% | +5.6% | |
| Q2 2023 | -9.3% | -19.9% | -15.4% | |
| Q1 2023 | -0.8% | -13.8% | +10.2% | |
| Q4 2022 | +14.6% | +24.5% | +20.5% | |
| Q3 2022 | -21.4% | -20.3% | -1.9% | |
| Q2 2022 | +5.9% | +1.0% | -15.9% | |
| Q1 2022 | -1.6% | -9.1% | -11.7% | |
| Q4 2021 | +3.7% | -1.3% | +6.5% | |
| Q3 2021 | -6.1% | -1.5% | -18.1% | |
| Q2 2021 | +12.8% | +11.6% | +16.9% | |
| Q1 2021 | +4.6% | -6.5% | -6.8% | |
| Q4 2020 | -3.1% | +8.6% | +1.7% | |
| Q3 2020 | -6.7% | -4.1% | +4.4% | |
| Q2 2020 | -28.8% | -33.2% | -44.6% | |
| Q1 2020 | -38.1% | -30.1% | -23.6% | |
| Q4 2019 | -43.7% | -44.0% | -39.0% | |
| Q3 2019 | -22.9% | -19.9% | -28.9% | |
| Q2 2019 | +3.3% | +6.1% | +4.3% | |
| Q1 2019 | -14.3% | -19.5% | -16.1% | |
| Q4 2018 | +15.0% | +16.0% | +13.0% | |
| Q3 2018 | +15.1% | +20.3% | +35.0% | |
| Q2 2018 | -1.7% | -4.2% | -7.5% | |
| Q1 2018 | -0.6% | +4.1% | +9.1% | |
| Q4 2017 | +11.0% | +10.1% | +28.6% | |
| Q3 2017 | +20.4% | +19.8% | +9.5% | |
| Q2 2017 | +6.6% | +3.2% | +23.6% | |
| Q1 2017 | -16.8% | -16.4% | -15.6% | |
| Q4 2016 | -34.3% | -28.2% | -32.4% | |
| Q3 2016 | -7.4% | — | — | |
| Q2 2016 | -7.1% | — | — | |
| Q1 2016 | +10.2% | — | — | |
| Q4 2015 | +5.0% | — | — | |
| Q3 2015 | -2.5% | — | — | |
| Q2 2015 | -7.4% | — | — | |
| Q1 2015 | -12.3% | — | — | |
| Q4 2014 | -5.8% | — | — | |
| Q3 2014 | -10.0% | — | — | |
| Q2 2014 | +14.1% | — | — | |
| Q1 2014 | -0.0% | — | — | |
| Q4 2013 | -7.7% | — | — | |
| Q3 2013 | +9.0% | — | — | |
| Q2 2013 | -2.6% | — | — | |
| Q1 2013 | +13.5% | — | — | |
| Q4 2012 | -1.0% | — | — | |
| Q3 2012 | +1.7% | — | — | |
| Q2 2012 | +3.1% | — | — | |
| Q1 2012 | -0.7% | — | — | |
| Q4 2009 | +4.7% | — | — | |
| Q4 2011 | +4.7% | — | — | |
| Q3 2010 | +5.7% | — | — | |
| Q3 2011 | +5.7% | — | — | |
| Q2 2011 | -0.7% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +5.5% | — | — | |
| Q1 2011 | +5.5% | — | — | |
| Q4 2010 | +5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro